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Summary  23 
Background and purpose 24 
The clinical use of cinacalcet in hyperparathyroidism is complicated by its tendency 25 
to induce hypocalcaemia, arising, at least in part, via activation of CaSRs in the 26 
thyroid and stimulation of calcitonin release.  CaSR allosteric modulators that 27 
selectively bias signalling of the receptor towards pathways that mediate desired 28 
effects (e.g. PTH suppression) at the exclusion of those that mediate undesirable 29 
effects (e.g. elevated serum calcitonin), may offer superior therapies.   30 
Experimental approach 31 
We characterised the ligand-biased profile of novel calcimimetics in HEK293 cells 32 
stably expressing the human CaSR and monitoring effects on Ca2+i mobilisation, IP1 33 
accumulation, pERK1/2 and receptor expression.   34 
Key results 35 
Phenylalkylamine calcimimetics were biased towards allosteric modulation of Ca2+i 36 
mobilisation and IP1 accumulation.  S,R-calcimimetic B was biased only towards IP1 37 
accumulation.  R,R-calcimimetic B  and AC-265347 were biased towards IP1 38 
accumulation and pERK1/2.  Nor-calcimimetic B was unbiased.  In contrast to 39 
phenylalkylamines and calcimimetic B analogues, AC-265347 did not promote 40 
trafficking of a loss-of-expression naturally occurring CaSR mutation (G670E).   41 
Conclusions and implications 42 
The ability of R,R-calcimimetic B and AC-265347 to bias signalling towards 43 
pERK1/2 and IP1 accumulation may explain their ability to suppress PTH levels in 44 
vivo at concentrations that have no effect on serum calcitonin levels.  The 45 
demonstration that AC-265347 promotes CaSR signalling but not trafficking reveals a 46 A
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novel profile of ligand-biased modulation at the CaSR.  The identification of allosteric 47 
modulators that bias CaSR signalling towards distinct intracellular pathways provides 48 
an opportunity to develop desirable biased signalling profiles in vivo for mediating 49 
selective physiological responses. 50 
 51 
 52 
Abbreviations:  53 
Ca2+o, extracellular calcium 54 
Ca2+i, intracellular calcium 55 
CaSR, calcium sensing receptor 56 
FHH, familial hypocalciuric hypercalcaemia  57 
Mg2+o, extracellular magnesium 58 
NSHPT, neonatal severe hyperparathyroidism 59 
pERK1/2, ERK1/2 phosphorylation 60 
PTH, parathyroid hormone 61 
 62 
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Introduction 66 
The human calcium sensing receptor (CaSR) is a family C G protein-coupled receptor 67 
(GPCR) primarily responsible for the regulation of extracellular calcium (Ca2+o) 68 
concentrations in the body.  When Ca2+o rises, activation of the CaSR expressed in the 69 
parathyroid gland suppresses the secretion of parathyroid hormone (PTH).  The drop 70 
in circulating PTH levels results in reduced renal Ca2+o reabsorption and reduced bone 71 
resorption (reviewed in Brown, 2013).  Additionally, CaSR activation in the kidney 72 
by elevated serum Ca2+o inhibits Ca2+o reabsorption, leading to enhanced renal Ca2+o 73 
excretion independently of changes in PTH (Kantham et al., 2009; Loupy et al., 74 
2012).  Elevated serum Ca2+o also decreases bone resorption via CaSRs expressed on 75 
osteoblasts and osteoclasts (see Marie, 2010 for a review) and by stimulation of 76 
calcitonin secretion via CaSRs expressed on thyroid C cells (Freichel et al., 1996).   77 
 78 
The CaSR also has non-calciostatic roles.  Thus, it mediates the modulation of blood 79 
pressure (see Smajilovic et al., 2011 for a review) and protection against vascular 80 
calcification (Alam et al., 2009), stimulation of gastrointestinal hormone secretion 81 
(Feng et al., 2010; Mace et al., 2012), modulation of electrolyte and water transport in 82 
the colon and kidney (reviewed in Macleod, 2013) and modulation of the proliferation 83 
and differentiation of numerous cell types, including colonic epithelial cells, 84 
keratinocytes, adipocytes and neurones.  85 
 86 
Given its ubiquitous expression throughout the body and functionally diverse roles, 87 
drugs that target the CaSR may have therapeutic application in various clinical 88 
contexts.  However, these drugs may also produce adverse effects arising from actions 89 A
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in multiple tissues expressing the CaSR.  Indeed, patients treated with the 90 
calcimimetic, cinacalcet (ĮR)-í-Į-methyl-N-[3-[3-[trifluoromethylphenyl]propyl]-91 
1-napthalenemethanamine hydrochloride), a positive allosteric CaSR modulator 92 
indicated for the treatment of secondary and some forms of primary 93 
hyperparathyroidism, have a tendency to develop adverse effects that restrict its use to 94 
only severely affected patients.  The most problematic adverse effect is 95 
hypocalcaemia (Chonchol et al., 2009), likely resulting from both suppressed renal 96 
calcium reabsorption induced by CaSR activation in the kidney, and calcitonin-97 
mediated inhibition of bone resorption via CaSR activation in the thyroid C-cells 98 
(Arenas et al., 2013).  Thus, novel calcimimetics that selectively stimulate CaSR-99 
mediated signalling in the parathyroid gland without affecting CaSRs in other tissues 100 
may have an improved side effect profile and enable treatment of less severe grades of 101 
hyperparathyroidism. 102 
 103 
One approach to directing desired physiological outcomes of GPCR activation is to 104 
selectively target those intracellular signalling pathways that couple to the anticipated 105 
effect, while avoiding those that couple to unwanted consequences.  Such selectivity 106 
can be achieved with a drug that binds to and favours a receptor conformation that 107 
preferentially couples to a subset of desired intracellular signalling pathways 108 
(Kenakin, 2011).  This concept is referred to as ligand-biased signalling, ligand-109 
directed trafficking of receptor stimulus, functional selectivity or biased agonism 110 
(Kenakin & Christopoulos, 2013). 111 
 112 
The CaSR is subject to ligand-biased signalling on a number of levels (Leach et al., 113 
2014).  First, it binds multiple endogenous ligands, including Ca2+o, Mg2+o, L-amino 114 A
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DFLGV SRO\DPLQHV DQG WKH JOXWDP\O SHSWLGH Ȗ-glutathione.  Ca2+o, spermine and L-115 
phenylalanine have been demonstrated to preferentially activate distinct signalling 116 
pathways (Rey et al., 2010; Thomsen et al., 2012a), suggesting that each ligand has 117 
the propensity to stabilise a subset of preferred receptor states and subsequently 118 
stimulate the repertoire of intracellular signalling proteins that couple to these states.  119 
Second, positive allosteric modulators of the CaSR, such as cinacalcet, and negative 120 
CaSR modulators (calcilytics), such as NPS-2143 (2-chloro-6-[(2R)-3-[[1,1-dimethyl-121 
2-(2-naphthalenyl)ethyl]amino-2-hydroxypropoxy]benzonitrile hydrochloride), 122 
engender biased allosteric modulation at the CaSR, such that they exhibit greater 123 
modulation of some pathways over others (Davey et al., 2012; Leach et al., 2013).  124 
7KLUGWKH³QDWXUDOELDV´RIWKH&D65FDQEHDOWHUHGLQSDWKRSK\VLRORJLFDOVWDWHV7KLV125 
has been demonstrated by naturally occurring mutations in the CaSR protein that alter 126 
its usual signalling bias (Leach et al., 2012), a switch in CaSR signalling from Gi/o to 127 
Gs in human breast cancer cells (Mamillapalli et al., 2008), and an autoantibody 128 
directed against the CaSR in a patient with acquired hypocalciuric hypercalcemia, 129 
which potentiated inositol phosphate (IP) accumulation, yet inhibited ERK1/2 130 
phosphorylation (pERK1/2) (Makita et al., 2007).  Finally, the complement of 131 
intracellular signalling proteins to which the CaSR couples differs between cell types, 132 
thus, the capacity of the CaSR to couple to different signalling pathways depends 133 
upon its tissue-specific expression.   134 
 135 
Proof-of-concept that tissue-specific effects can be achieved by targeting the CaSR 136 
with drugs was evident from early experiments with the prototypical calcimimetic, 137 
NPS-R568.  During the development of the phenylalkylamine calcimimetics (e.g. 138 
NPS-R568 and cinacalcet), it was recognised that the natural hypocalcaemic effects of 139 A
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these drugs may be complicated by stimulation of calcitonin release via activation of 140 
CaSRs in the thyroid.  Thus, the need to suppress PTH secretion with minimal effects 141 
on calcitonin secretion was acknowledged (Fox et al., 1999a; Fox et al., 1999b), but 142 
remains sub optimally addressed.  143 
 144 
Third generation agents appear to have enhanced tissue-selective effects.  This is 145 
evident from studies with the novel dibenzylamine calcimimetic, R,R-calcimimetic B 146 
(R-1-(6-methoxy-¶-(trifluoromethyl)-3-biphenylyl)-N-(R)-1-phenylethyl)ethanamine) 147 
and the structurally distinct calcimimetic, AC-265347 (1-benzothiazol-2-yl-1-(2,4-148 
dimethyl-phenyl)-ethanol).  Both calcimimetics inhibit PTH secretion at 149 
concentrations that do not induce calcitonin release in rats (Henley et al., 2011; Ma et 150 
al., 2011), demonstrating a means for normalising serum PTH and calcium levels 151 
without causing uncontrolled hypocalcaemia.  How these compounds achieve this 152 
tissue specificity is unknown, but we hypothesise that it may be a result of ligand-153 
biased allosteric modulation at the CaSR.  This is based on the fact that distinct 154 
intracellular signalling pathways activated by the CaSR are responsible for its 155 
physiological effects, thus drugs may selectively promote suppression of PTH release 156 
by preferentially activating the pathways that couple to that response.  For instance, 157 
CaSR suppression of PTH release is driven by phospholipase C (PLC)-mediated IP3 158 
production (Brown et al., 1987; Kifor et al., 1997) and pERK1/2 (Corbetta et al., 159 
2002) but there is some evidence that CaSR-mediated Ca2+i release is not required for 160 
inhibition of PTH from bovine parathyroid cells (Russell et al., 1999).  Stimulation of 161 
both PLC and Ca2+i mobilisation have been linked to the release of calcitonin (Liu et 162 
al., 2003; McGehee et al., 1997; Thomsen et al., 2012b) but in rat 6-23 medullary 163 
thyroid carcinoma cells, inhibition of pERK1/2 has no effect on Ca2+o-mediated 164 A
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stimulation of calcitonin release (Thomsen et al., 2012b).  Thus, drugs that bias CaSR 165 
signalling towards pERK1/2 may achieve tissue-selective suppression of PTH 166 
secretion in the absence of calcitonin release.  167 
 168 
To probe the ligand-biased signalling profile(s) required to achieve drug tissue 169 
selectivity, pathways that mediate distinct physiological receptor functions should 170 
ideally be dissected in systems such as primary or immortalised cells that maintain 171 
their physiological function.  However, for the CaSR, this has been hampered by a 172 
lack of relevant cell lines and methods to study, for instance, parathyroid cell 173 
function.  We have developed techniques to measure signalling in, and PTH release 174 
from, primary human parathyroid cells (Avlani et al., 2013; Broadhead et al., 2011; 175 
Mun et al., 2009) but performing high throughput experiments in these cells is at 176 
present not possible.  Thus, most studies of this nature must rely on recombinant cell 177 
systems to investigate CaSR signalling in response to agonists and drugs.  178 
Nonetheless, recombinant systems can still be used to identify bias and validate 179 
whether compounds with desirable in vivo properties have unique pharmacology in 180 
vitro, and vice versa. 181 
 182 
The current study thus primarily aimed to use a recombinant cell system to determine 183 
the potential for structurally distinct calcimimetics to engender ligand-biased 184 
signalling and subsequently promote coupling of the CaSR to three key signalling 185 
pathways that could mediate different physiological effects; IP1 accumulation (a stable 186 
metabolite of IP3), Ca2+i mobilisation and pERK1/2.  Furthermore, we have 187 
previously shown that CaSR modulators can be biased in their ability to modulate 188 
signalling versus trafficking at the CaSR (Leach et al., 2013).  Therefore, in addition 189 A
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to acute signalling at the CaSR, we determined the ability of the calcimimetics to act 190 
as pharmacochaperones of a naturally occurring mutant CaSR, G670E.  Differential 191 
effects on trafficking versus signalling may have important implications for the 192 
treatment of calcium handling disorders caused by mutations in the CaSR gene that 193 
result in a diverse range of molecular phenotypes. 194 
 195 
Materials and Methods 196 
 197 
Synthesis of calcimimetics 198 
Synthesis of R,R-calcimimetic B (compound 3b ± appendix S1), its diastereoisomer 199 
S,R-calcimimetic B (compound 3a ± appendix S1) and nor-calcimimetic B 200 
(compound 3c ± appendix S1) was achieved using a two-step procedure derived from 201 
described literature (Harrington et al., 2010).  Full synthetic details and compound 202 
characterisation are given in Appendix S1.  NPS-R568 and cinacalcet were prepared 203 
as described previously (Davey et al., 2012).  Calindol was purchased from Tocris 204 
Biosciences, whereas AC-265347 was from Sigma-Aldrich. 205 
 206 
Cell culture 207 
Generation of FlpIn HEK293 TRex cells (Invitrogen) stably expressing the human 208 
CaSR under the control of tetracycline has been described previously (Davey et al., 209 
2012; Leach et al., 2012).  Cells were maintained in DMEM with 10% FBS, 200 Pg 210 
ml-1 hygromycin B and 5 Pg ml-1 blasticidin.   211 
 212 
Optimisation of assay conditions 213 A
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The effect of ambient buffer Ca2+o on allosteric modulation at the CaSR has 214 
previously been published by us (Davey et al., 2012).  Because Ca2+o is both present 215 
in the buffer and added as the agonist, assay buffer Ca2+o was optimised to achieve the 216 
best possible assay signal while avoiding complications that arise from the presence 217 
of physiological Ca2+o concentrations (e.g. signalling desensitisation, potentiation of 218 
ambient Ca2+o signalling).  In this same cell system, Mg2+o is nearly 3 fold less potent 219 
than Ca2+o as a CaSR agonist (data not shown).  Thus, the presence of 1.18mM 220 
ambient Mg2+o has minimal effect on CaSR signalling.  Therefore, all assays were 221 
performed under low Ca2+o but physiologically relevant Mg2+o conditions.  For 222 
concentration-response curves to Ca2+o, data are plotted and analysed without the 223 
ambient Ca2+o concentration (i.e. only the added Ca2+o is considered). 224 
 225 
Ca2+i mobilisation assays 226 
Cells were seeded in a clear 96-well plate coated with poly-D-lysine (50 Pg ml-1) at 227 
80,000 cells per well and incubated overnight in the presence of 100 ng ml-1 228 
WHWUDF\FOLQH7KHIROORZLQJGD\FHOOVZHUHZDVKHGZLWKȝODVVD\EXIIHUP0229 
NaCl, 2.6 mM KCl, 1.18 mM MgCl2, 10 mM D-Glucose, 10 mM HEPES, 0.1 mM 230 
Ca2+o%6$DQGP0SUREHQHFLGDWS+DQG ORDGHGZLWKȝO)OXR-4 231 
$0ȝ0IRUKDW oC. 232 
 233 
&HOOVZHUHZDVKHGDJDLQZLWKȝODVVD\EXIIHUSULRUWRWKHDGGLWLRQRIIUHVKDVVD\234 
buffer.  In functional interaction studies between Ca2+o and the calcimimetics, the 235 
modulators were coadded with Ca2+o (in all assays measuring agonist-stimulated 236 
receptor signalling events, each well was treated with a single agonist and/or 237 
modulator concentration).  The release of Ca2+i was measured at 37°C using a 238 A
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Flexstation® 1 or 3 (Molecular Devices; Sunnyvale, California).  Fluorescence was 239 
detected for 60 s at 485 nm excitation and 525 nm emission but the peak Ca2+i 240 
mobilisation response (approximately 12 seconds after agonist addition) was used for 241 
the subsequent determination of the agonist response.  We have previously shown that 242 
when allosterism at the CaSR is quantified in Ca2+i mobilisation assays using the 243 
potency of Ca2+o obtained by plotting the area under the 60 second Ca2+i mobilisation 244 
trace, no significant difference in signalling or biased modulation is observed in 245 
comparison to parameters derived using the peak Ca2+i mobilisation response (Leach 246 
et al., 2013). Relative peak fluorescence units were normalised to the fluorescence 247 
stimulated by ionomycin to account for differences in cell number and loading 248 
efficiency, and further normalised to the maximum response observed for the WT 249 
CaSR in the absence of modulator. 250 
 251 
Extracellular regulated kinase 1/2 (ERK1/2) phosphorylation assays 252 
Cells were seeded at 80,000 cells per well into a poly-D-lysine coated (50 Pg ml-1) 253 
transparent 96-well plate and grown overnight with 100 ng ml-1 tetracycline.  The 254 
following day, cells were washed twice with PBS and serum-free DMEM containing 255 
16 mM HEPES and 0.1 mM Ca2+o was added to wells.  Vehicle or agonist (Ca2+o) 256 
with or without modulator were coadded to wells and incubated for 2.5 minutes (the 257 
time determined in prior assays for pERK1/2 to peak) at 37°C.  All data were 258 
normalised to the response stimulated by 10% FBS and then further normalised to the 259 
maximum response stimulated by Ca2+o in the absence of modulator.  pERK1/2 was 260 
determined using the SureFire pERK1/2 assay kit (kindly donated by Dr Michael 261 
Crouch, TGR biosciences, Adelaide) employing AlphaScreen technology 262 A
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(PerkinElmer). All other details are as described previously (Leach et al., 2013; Leach 263 
et al., 2012). 264 
 265 
IPone accumulation assays 266 
Following overnight induction of receptor expression with 100 ng ml-1 tetracycline in 267 
a T175cm2 flask (where appropriate), cells were harvested and resuspended in assay 268 
buffer (150 mM NaCl, 2.6 mM KCl, 1.18 mM MgCl2, 10 mM D-Glucose, 10 mM 269 
HEPES, 0.1 mM Ca2+o, 50 mM LiCl, pH 7.4) at 1.43 x 106 cells ml-1.  7 Pl agonist 270 
with or without modulator were added to wells of a 384 well white proxiplate 271 
(PerkinElmer) and 7 Pl cells (1x104 cells) were added to these wells, centrifuged for 1 272 
minute at 350 x g and incubated at 37°C for 45 minutes.  The IP-2QH7EDVVD\NLW273 
(CisBio, France) was used to detect myo-inositol 1 phosphate (IP1), based on 274 
fluorescence resonance energy transfer (FRET) between d2-conjugated IP1 and 275 
/XPL-Tb cryptate conjugated anti-IP1 antibody.  These reagents were diluted 1:30 276 
with lysis buffer and 3 Pl of each was added to wells following agonist stimulation.  277 
Lysates were incubated for 1 hour and FRET was detected using an Envision plate 278 
UHDGHU3HUNLQ(OPHUZKHUHHPLVVLRQRI/XPL-Tb cryptate was detected at 620 nm 279 
and emission of d2-conjugated IP1 at 665 nm.  Results were calculated from the 665 280 
nm / 620 nm ratio.  Data were normalised to the maximum response stimulated by 281 
Ca2+o in the absence of modulator. 282 
 283 
Flow cytometry analysis for receptor expression 284 
FlpIn HEK293 TRex cells stably expressing the human wild-type (WT) or G670E 285 
mutant CaSR were seeded in a 96-well plate at a density of 80,000 cells per well in 286 
DMEM containing 100 ng ml-1 tetracycline and 0.3 PM or 3 ȝ0DOORVWHULFPRGXODWRU287 A
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and incubated overnight at 37°C.  The next day, cells were harvested with PBS 288 
supplemented with 0.1 % BSA, 2 mM EDTA and 0.05% NaN3 (washing buffer) and 289 
transferred to wells of a 96 well v-bottom plate, centrifuged for 3 min at 350 x g, 4°C 290 
and resuspended in 100 Pl blocking buffer (PBS, 5% BSA, 2 mM EDTA and 0.05% 291 
NaN3).  Cells were incubated for 30 min in blocking buffer and subsequently 292 
incubated for 1 h with an AF647-conjugated 9E10 antibody (made in-house as 293 
GHVFULEHG EHORZ GLOXWHG LQ EORFNLQJ EXIIHU DW  ȝJ PO-1. Cells were subsequently 294 
washed with washing buffer and resuspended in washing buffer with Sytox blue stain 295 
(Molecular probes).  The fluorescence signal was quantified using a FACS Canto 296 
(Becton Dickinson). 297 
 298 
Production of anti-cMyc:AF647 (9E10:AF647) 299 
Supernatant from the 9E10 hybridoma (ATCC Number: CRL-1729) was harvested 300 
and antibody purified over a HiTrap protein G sepharose column (GE Lifesciences). 301 
The purified antibody was coupled to AF647 Succinimidyl Ester (Life technologies) 302 
using standard protocols. Unincorporated fluor was removed using a 10kDa MWCO 303 
centrifugal concentrator (Merck Millipore). Degree of labeling was determined to be 304 
3.6. The antibody conjugate was validated by titration in flow cytometry. A full 305 
description of antibody production, conjugation and validation can be found in the 306 
supplementary methods and results. 307 
 308 
Data analysis 309 
All nonlinear regression analysis was performed using GraphPad Prism® 6 (GraphPad 310 
Software, San Diego, CA).  Parametric measures of potency, affinity and 311 
cooperativity were estimated as logarithms (Christopoulos, 1998).  Data of the 312 A
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functional CaSR concentration response curves obtained were fitted as logarithms to 313 
the following four-parameter concentration response curve equation (Equation 1) 314 
Y=Bottom+(Top-Bottom) ´ (A
nH )
AnH +EC50
nH
   (1)
 315 
where Y is the response, Bottom and Top represent the bottom and top asymptotes of 316 
the curve, respectively, A denotes the agonist concentration (excluding ambient Ca2+o 317 
in the buffer), nH (Hill slope) describes the steepness of the curve, EC50 is the 318 
concentration of agonist that gives the mid-point response between Bottom and Top. 319 
 320 
For functional interaction experiments between Ca2+o and the allosteric modulators, 321 
pEC50 values obtained for each curve in the absence and presence of modulator were 322 
fitted to an allosteric ternary complex model (Equation 2) 323 
  pEC50 =Log 10
Loga b u [B] +10-pKBª¬ º¼ - Logd   (2) 324 
where pEC50 is the negative logarithm of the agonist EC50 in the presence of allosteric 325 
modulator, pKB is the QHJDWLYHORJDULWKPRIWKH³IXQFWLRQDO´GLVVRFLDWLRQFRQVWDQWRI326 
the allosteric modulator determined in signalling assays, ǩ E is the overall 327 
cooperativity between the allosteric modulator and orthosteric agonist, and d is the 328 
estimate of the EC50 in the absence of modulator.  An extra sum of squares F test was 329 
used to determine whether data obtained in IP1 accumulation, Ca2+i mobilisation and 330 
pERK1/2 assays were fitted best when the allosteric modulator functional pKB values 331 
were shared across the three different pathways.  In a second analysis that constrained 332 
the functional pKB across datasets (Supplemental Table 1, Supplemental Figure 9), an 333 
extra sum of squares F test was used to determine whether the cooperativities between 334 
the three pathways differed.  335 
 336 A
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)RUWKH³FRRSHUDWLYLW\ELDVSORW´ WKHS(&50 of Ca2+o in the absence and presence of 337 
modulator in IP1 accumulation, Ca2+i mobilisation and pERK1/2 assays was first fitted 338 
to equation 2 and 150 XY coordinates of points that defined the curve that best fit 339 
equation 2 were determined.  Next, the XY coordinates for the different pathways 340 
were plotted against one another, with IP1 accumulation or Ca2+i mobilisation data on 341 
the y-axis against pERK1/2 data on the x-axis.  XY coordinates corresponding to the 342 
efIHFWVRIDQGȝ0PRGXODWRUDUHUHVSUHVHQWHGE\343 
symbols on the plots.  If the allosteric modulator shows equal cooperativity in the 344 
assays, the data points will be coincident and the cooperativity bias plots will overlap 345 
with the line of identity.  If, however, the modulator exerts greater cooperativity in 346 
one of the pathways, the points will fall either side of this line towards the preferred 347 
pathway.   348 
  349 
For agonist concentration response curves in the absence of Ca2+o and Mg2+o, data 350 
were fitted as logarithms to an operational model of agonism (Equation 3) 351 
E=
E
m
´ t
B
´ [Bn ]
KB+[Bn ] ´ t B+1( )       (3) 352 
where E is the effect (response) stimulated by the allosteric agonist, Em is the 353 
maximum response of the system stimulated by the full agonist (Ca2+o), ĲB is an 354 
operational measure of allosteric agonist efficacy, defined as the inverse of the 355 
fraction of receptors that must be occupied by agonist to obtain the half-maximal 356 
response, [B] is the allosteric agonist concentration and n is the transducer slope.  357 
 358 
Results 359 
Rationale for choice of ligands and signalling pathways 360 A
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The structures of the calcimimetics used in this study are shown in Figure 1.  The 361 
prototypical phenylalkylamine calcimimetics, cinacalcet and NPS-R568 (3-(2-362 
chlorophenyl)-N-((1R)-1-(3-methoxyphenyl)ethyl)-1-propanamine) have been well 363 
characterised in vitro and in vivo (Nemeth et al., 2004; Nemeth et al., 1998).  Calindol 364 
((R)-2-[N-(1-(1-naphthyl)ethyl)aminomethyl]indole) was the most potent 365 
calcimimetic identified at the Institut de Chimie des Substances Naturelles (ICSN, 366 
France) from a series of diamines based around the structure of NPS-R568 (Kessler et 367 
al., 2004).  R,R-calcimimetic B was the most potent CaSR ligand identified by Amgen 368 
in a dibenzylamine series and exhibited ideal in vivo pharmacodynamics.  In an IP 369 
accumulation assay, R,R-calcimimetic B was estimated to have greater affinity than 370 
NPS-R568 (Harrington et al., 2010; Henley et al., 2011).  The published synthesis of 371 
R,R-calcimimetic B employed a route yielding a diastereomeric ratio (d.r.) of 14:1 of 372 
R,R-calcimimetic B and the corresponding S,R-diastereoisomer (S-1-(6-methoxy-¶-373 
(trifluoromethyl)-3-biphenylyl)-N-(R)-1-phenylethyl)ethanamine) respectively, which 374 
were then separated via HPLC (Harrington et al., 2010).  S,R-calcimimetic B was 375 
100-fold less potent than R,R-calcimimetic B (Harrington et al., 2010), comparable to 376 
the stereoselectivity of the R- and S-isomers of NPS- 568 and cinacalcet (Hammerland 377 
et al., 1998; Nemeth et al., 2004).  Given the remarkable difference in potency of the 378 
individual diastereoisomers, we sought to isolate and further characterise each one 379 
independently.  Adapting the synthesis of Harrington et al, we were able to generate a 380 
mixture of diastereoisomers with a d.r. of 4:1. These were successfully isolated by 381 
either chiral HPLC or preparative layer chromatography (PLC) (see Appendix S1 for 382 
full synthetic methods). Structurally, the contrasting pharmacological behaviour of 383 
each diastereoisomer can be attributed to the spatial orientation of the methyl group 384 
adjacent to the biphenyl and amino moieties. With this in mind, it was of interest to 385 A
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evaluate the pharmacological activity of the µQRU¶FDOFLPLPHWLF%GHULYDWLYH(R-N-((6-386 
methoxy-¶-(trifluoromethyl)-3-biphenylyl)methyl)-1-phenylethanamine), with a 387 
methylene group replacing the methyl of interest. This was synthesised in a similar 388 
fashion to the R,R- and S,R-calcimimetic B derivatives.  AC-265347 was identified in 389 
a screen by ACADIA Pharmaceuticals as a potent calcimimetic.  It is structurally 390 
distinct from the phenylalkylamine calcimimetics and calcimimetic B, and was found 391 
to have improved potency over cinacalcet in an IP accumulation assay (Ma et al., 392 
2011).  393 
 394 
We investigated the effects of the calcimimetics in Ca2+i mobilisation, IP 395 
accumulation and pERK1/2 assays because each of these pathways has been 396 
undeniably linked to CaSR regulation of PTH release from parathyroid chief cells 397 
and/or calcitonin release from thyroid C cells, as outlined in the introduction.  398 
Although additional pathways are also involved in the regulation of PTH and 399 
calcitonin release, we selected those for which assays can be reliably performed in a 400 
high throughput manner to enable robust quantification of allosteric modulation and 401 
biased signalling. 402 
 403 
Calcimimetics are biased modulators of CaSR signalling 404 
To evaluate the extent to which calcimimetics engender ligand-biased modulation at 405 
the CaSR, we first characterised their ability to potentiate the endogenous agonist, 406 
Ca2+o, in IP1 accumulation, Ca2+i mobilisation and pERK1/2 assays.  These 407 
experiments generated Ca2+o concentration-response curves in the absence and 408 
presence of the allosteric modulators.  409 
 410 A
cc
ep
te
d
 A
rt
ic
le
As expected, cinacalcet, NPS-R568, calindol, AC-265347, R,R-calcimimetic B, S,R-411 
calcimimetic B and nor-calcimimetic B, potentiated agonist-mediated activation of the 412 
CaSR in each assay, demonstrated by a leftward shift in the Ca2+o concentration-413 
response curve, and a consequent increase in Ca2+o potency.  In some instances, the 414 
calcimimetics elicited a concomitant increase in the baseline response due to 415 
potentiation of Ca2+o and Mg2+o in the buffer (Davey et al., 2012) and/or agonist 416 
activity.  No changes in the maximum response elicited by Ca2+o were observed in the 417 
presence of the calcimimetics.  Experimental data from IP1 accumulation assays for a 418 
representative calcimimetic from each class of compound are shown in Figure 2.  419 
Data for all calcimimetics across each pathway are shown in Appendix S3, 420 
Supplemental Figures 2-8. 421 
 422 
We have previously demonstrated that both calcimimetics and calcilytics can exhibit 423 
biased allosteric modulation via two (albeit related) mechanisms.  The first arises 424 
from the ability of modulators to bind with distinct affinities to CaSR conformations 425 
that mediate different signalling pathways (Davey et al., 2012).  Divergent affinities 426 
indicate that the modulators stabilise distinct receptor states, a requirement of ligand-427 
biased signalling.  The second arises from cooperativities between a modulator and 428 
the orthosteric agonist that differ at a given receptor state (Davey et al., 2012; Leach 429 
et al., 2013).  Thus, an allosteric ternary complex model (equation 2) was used to 430 
quantify the parameters that governed the activity of the calcimimetics in each assay 431 
to estimate the functional affinity (functional pKB) of the modulators and their overall 432 
cooperativity (ǩǪ) with Ca2+o (Table 1).  An F-test was used to determine whether 433 
the functional affinity and/or cooperativity of each calcimimetic differed across 434 
signalling assays.  However, because functional affinity and cooperativity parameters 435 A
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are correlated in the nonlinear regression algorithgm, it is sometimes difficult to 436 
separate out the two effects.  Thus, results of nonlinear regression analyses that 437 
assumed the binding affinity to be the same or not the same across pathways are 438 
presented in Appendices 2 and 3 of the Supplemental data.   439 
 440 
These analyses established a number of key findings.  First, the phenylalkylamine 441 
calcimimetics, NPS-R568 and calindol, exhibited ligand-biased modulation that 442 
favoured activation of Ca2+i mobilisation and IP1 accumulation.  This was manifested 443 
as a lower functional affinity for the receptor state that coupled to pERK1/2 (Table 2, 444 
Figure 3A).  Cinacalcet also demonstrated a tendency to modulate pERK1/2 less 445 
favourably than the other two pathways (Table 2, Figure 3A and B), but significance 446 
for this effect was only reached if its functional affinity was assumed to be the same 447 
across pathways (Supplemental Table 1, Supplemental Figure 9) and was thus 448 
indicative of weaker cooperativity in pERK1/2 assays.  Second, S,R-calcimimetic B 449 
was biased towards modulation of IP1 accumulation, but showed no preference 450 
between Ca2+i mobilisation or pERK1/2.  Similar to cinacalcet, significance was only 451 
reached when its functional affinity was assumed to be the same across pathways 452 
(Supplemental Table 1, Supplemental Figure 9).  Third, nor-calcimimetic B was 453 
relatively unbiased in its ability to modulate the three pathways, and its estimated 454 
functional affinities and cooperativities were comparable in all three assays.  Finally, 455 
R,R-calcimimetic B and AC-265347 were biased towards modulation of pERK1/2 and 456 
IP1 accumulation, either in terms of functional affinity (Figure 3A) or cooperativity 457 
(Figure 3B and Supplemental Figure 9).  The bias arising from AC-265347 can be 458 
visualised in Figures 4A-C where the different effects of 0.1PM AC-265347 on Ca2+o 459 
signalling in the three different assays are apparent.  The bias engendered by multiple 460 A
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concentrations of AC-FDQEHYLVXDOLVHG LQ WKHPRGXODWRU³FRRSHUDWLYLW\ELDV461 
SORW´ DV VKRZQ LQ )LJXUH '  7KLV LOOXVWUDWHV the impact of equivalent AC-265347 462 
concentrations on Ca2+o potency in Ca2+i mobilisation or IP1 assays on the y-axis, and 463 
pERK1/2 assays on the x-axis.  If AC-265347 modulated both pathways equally, the 464 
data would converge on the line of identity.  However, because it modulates one 465 
pathway to a greater degree than the other, the data points are distributed away from 466 
the line of identity towards the preferred pathway (i.e. towards IP1 over pERK1/2 and 467 
towards pERK1/2 over Ca2+i).  468 
  469 
Third generation calcimimetics are agonists at the CaSR  470 
In IP1 accumulation and Ca2+i mobilisation assays, the calcimimetics stimulated 471 
receptor activity in the presence of vehicle (buffer) alone.  AC-265347, R,R-472 
calcimimetic B and nor-calcimimetic B also did so in pERK1/2 assays.  We 473 
previously simulated the effects of cinacalcet on signalling in the presence of an 474 
ambient concentration of agonist to reconstruct the experimental conditions under 475 
which our Ca2+i mobilisation and pERK1/2 assays are undertaken (Davey et al., 476 
2012).  These simulations suggested that positive modulation of ambient agonists in 477 
the buffer (Ca2+o and Mg2+o) was expected.  Accordingly, when we omitted ambient 478 
Ca2+o and Mg2+o from the assay buffer, Ca2+i mobilisation and IP1 accumulation 479 
stimulated by cinacalcet, NPS-R568 and calindol on their own was largely inhibited 480 
)LJXUH  LQGLFDWLQJ WKDW WKH REVHUYHG ³EDVHOLQH HIIHFW´ ZDV SULPDULO\ GXH WR481 
potentiation of ambient agonist activity.  In contrast, AC-265347 and the calcimimetic 482 
B analogues retained activity in the absence of ambient Ca2+o and Mg2+o (Figure 5).  483 
The effects of omitting only Ca2+o from the buffer can be observed in Supplemental 484 
Figure 10.   485 A
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 486 
We fitted the agonist activity of the calcimimetics (in the absence of Ca2+o and Mg2+o) 487 
to the standard operational model of agonism (Equation 3) (Black & Leff, 1983) to 488 
gain a second estimate of the functional affinity of the modulators at the CaSR.  These 489 
estimates were similar to the affinities estimated for the modulators using the 490 
allosteric ternary complex model (Table 2).  Of note is the comparable affinity of AC-491 
265347 between Ca2+i mobilisation and IP1 assays.  This is in contrast to its affinity in 492 
³SRWHQWLDWLRQ DVVD\V´ ZKLFK ZHUH VWURQJO\ VXJJHVWLYH RI D KLJKHU DIILQLW\ IRU WKH493 
receptor state that coupled to IP1 accumulation (Table 1, Figure 3A, Supplemental 494 
Figure 8).  Thus, the receptor state that mediates direct calcimimetic activation of the 495 
CaSR may be distinct from the state that modulates Ca2+o activity at the receptor. 496 
 497 
Our analysis additionally derived an operational measure of agonism, defined as ǼB, 498 
which reflects both the degree to which the agonist can activate the receptor, and the 499 
stimulus-response coupling between the receptor and the intracellular signalling 500 
pathway.  Interestingly, although Ca2+o is more potent in Ca2+i mobilisation than IP1 501 
assays, there was no significant difference in the activity of the modulators in the two 502 
assays (p > 0.1 unpaired t-test), indicating that they do not follow the same natural 503 
biased profile as the endogenous agonist.  504 
 505 
Calcimimetics differentially modulate trafficking of a naturally occurring loss-of-506 
expression mutant 507 
We have previously shown that both calcimimetics and calcilytics are also biased in 508 
their abilities to modulate CaSR trafficking (Leach et al., 2013).  This may have 509 
important implications for patients with loss-of-expression CaSR mutations that cause 510 A
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disorders of calcium metabolism such as familial hypocalciuric hypercalcaemia 511 
(FHH) and neonatal severe hyperparathyroidism (NSHPT).  Thus, to determine the 512 
ability of each of the CaSR modulators to correct trafficking and signalling of 513 
defective CaSR mutants, we investigated the consequences of the modulators at the 514 
naturally occurring loss-of-expression mutant, G670E (Kobayashi et al., 1997).  515 
Expression of this mutant receptor at the cell surface is greatly reduced but its affinity 516 
for cinacalcet is unaltered (Leach et al., 2013; Leach et al., 2012).  This mutant also 517 
signals efficiently in Ca2+i mobilisation and pERK1/2 assays (Leach et al., 2013; 518 
Leach et al., 2012).   519 
 520 
The affinities and cooperativities of AC-265347, cinacalcet, NPS-R568 and calindol 521 
were unaltered at the G670E mutation compared to the wildtype, as assessed in Ca2+i 522 
mobilisation assays (Table 3).  The affinity of the calcimimetic B analogues, however, 523 
was reduced approximately 100-fold, although R,R-calcimimetic B and nor-524 
calcimimetic B were still able to bind to the receptor and potentiate Ca2+o-mediated 525 
signalling.    526 
 527 
Overnight treatment of HEK293 cells with cinacalcet, NPS-R568, calindol, R,R-528 
calcimimetic B and nor-calcimimetic B restored cell surface expression of the G670E 529 
mutant (Table 3; Figure 6).  S,R-calcimimetic B and AC-265347, however, had no 530 
effect on expression.  In the case of S,R-calcimimetic B, this was likely due to lower 531 
receptor occupancy in comparison to the other calcimimetics due to its reduced 532 
functional affinity.  The inability of AC-265347 to rescue G670E expression, however, 533 
was not due to reduced affinity or to reduced cooperativity, which were comparable to 534 
the other calcimimetics.  The inability of AC-265347 to restore trafficking may be 535 A
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related to its lower lipophilicity relative to the other compounds.  This parameter can 536 
be represented by calculated partition coefficient (CLog P, see Figure 1), which for 537 
AC-265347 was found to be considerably lower than for the other allosteric 538 
modulators tested.  Thus, AC-265347 may have a reduced propensity to cross cell 539 
membranes to pharmacochaperone misfolded receptors trapped in the ER and Golgi 540 
compartments.   541 
 542 
Discussion 543 
The present study evaluated the pharmacological activity of structurally related and 544 
diverse calcimimetics across multiple measures of receptor activity, identifying 545 
distinct ligand-biased profiles for each compound.  Importantly, whereas 546 
phenylalkylamine modulators are biased towards Ca2+i mobilisation and IP1 547 
accumulation, S,R-calcimimetic B is biased only towards modulation of IP1 548 
accumulation, and nor-calcimimetic B is unbiased.  R,R-calcimimetic B and AC-549 
265347 on the other hand are biased towards pERK1/2 and IP1 accumulation.  Of 550 
note, although Ca2+i mobilisation via Gq-coupled receptors typically stems from the 551 
PLC-IP pathway, the divergence in bias between Ca2+i and IP1 assays observed herein 552 
suggests that CaSR-mediated Ca2+i mobilisation is also facilitated via alternative 553 
mechanisms.  This is supported by a number of previous findings.  In rat medullary 554 
thyroid carcinoma cells, Ca2+o activation of the CaSR resulted in Ca2+i influx via ion-555 
gated calcium channels in addition to IP3-mediated calcium mobilisation (Thomsen et 556 
al., 2012b).  Sr2+o, on the other hand, stimulated CaSR-mediated PLC/IP3/Ca2+i 557 
mobilisation, but did not trigger opening of calcium channels in these cells (Thomsen 558 
et al., 2012b).  Similarly, although both Ca2+o and L-phenylalanine stimulated Ca2+i 559 
mobilisation in CaSR-transfected HEK293 cells, only Ca2+o promoted IP 560 A
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accumulation and diacylglycerol production (Rey et al., 2005). Finally, we recently 561 
showed that truncation of the CaSR after R866 resulted in a complete inability of the 562 
receptor to stimulate Ca2+i mobilisation, whereas IP accumulation was reduced, but 563 
maintained (Goolam et al., 2014).  In the same study, mutations in intracellular loops 564 
2 and 3 greatly impaired IP accumulation but had a weaker affect on Ca2+i 565 
mobilisation.  These findings suggest Ca2+i mobilisation stimulated from the CaSR is 566 
in part driven via an IP-independent mechanism. 567 
  568 
Intriguingly, although AC-265347 is a positive modulator of CaSR signalling, it is a 569 
neutral modulator of receptor trafficking.  These findings build on our earlier studies 570 
of prototypical CaSR positive and negative allosteric modulators that initially 571 
identified bias in modulation by these compounds (Davey et al., 2012; Leach et al., 572 
2013). 573 
 574 
Ligand-biased signalling by CaSR modulators may be driven by ligand-specific 575 
stabilisation of distinct receptor states that couple preferentially to particular 576 
intracellular signalling pathways.  This is suggested by the different functional 577 
affinities or cooperativities with the endogenous agonist estimated at each pathway.  578 
We introduced this concept several years ago (Leach et al., 2007) and have 579 
subsequently observed biased allosteric modulation at the M4 muscarinic (Leach et 580 
al., 2010), A1 adenosine (Aurelio et al., 2009) and glucagon-like peptide 1 (GLP-1) 581 
(Koole et al., 2011) receptors, indicating that pathway selectivity may be achieved 582 
with allosteric modulators acting at a number of GPCRs. 583 
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AC-265347 exhibited high cooperativity in pERK1/2 assays, maximally enhancing 585 
the potency of Ca2+o nearly 10-fold, in comparison to the 3-fold enhancement in 586 
potency observed with cinacalcet.  This is consistent with previous findings indicating 587 
that AC-265347 is more potent than cinacalcet with respect to IP1 accumulation 588 
assays but has comparable potency with respect to cellular proliferation (Ma et al., 589 
2011).  This suggests that AC-265347 exhibits ligand-biased modulation of distinct 590 
CaSR signalling pathways.  pERK1/2 plays a significant role in the suppression of 591 
PTH release (Corbetta et al., 2002; Thomsen et al., 2012b) but may be less important 592 
for CaSR-mediated stimulation of calcitonin release (Thomsen et al., 2012b).  Thus, 593 
compounds that favour pERK1/2 over Ca2+i mobilisation may have reduced 594 
propensity to induce calcitonin-dependent hypocalcaemia when compared to 595 
cinacalcet.  Accordingly, there is pronounced separation (300-fold) in the 596 
concentration of S-AC-265347 required to suppress serum PTH levels versus the 597 
concentration that reduces serum Ca2+o levels in healthy rats (Ma et al., 2011).  598 
Similarly, concentrations of calcimimetic B that maximally inhibit PTH secretion in 599 
nephrectomised rats have little effect on calcitonin release or serum Ca2+o levels 600 
(Henley et al., 2011).  In contrast, cinacalcet concentrations required to maximally 601 
suppress PTH secretion also stimulate calcitonin release and reduce serum Ca2+o 602 
levels in rats (Nemeth et al., 2004), suggesting less selectivity of cinacalcet for 603 
suppression of PTH release.  AC-265347 and R,R-calcimimetic B are thus potentially 604 
important lead compounds of value in elucidating the roles of pERK1/2 in CaSR-605 
mediated regulation of PTH and calcitonin release. 606 
 607 
The fact that third generation but not phenylalkylamine calcimimetics are agonists in 608 
their own right may also contribute to their parathyroid selectivity.  When stimulus-609 A
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response coupling is strong, for instance in tissues such as the parathyroid glands 610 
where CaSR expression is high, partial agonist effects will become more pronounced. 611 
 612 
The CaSR is promiscuous in its coupling to intracellular signalling pathways, and the 613 
influence of individual pathways to physiological outcomes such as regulation of 614 
hormone release from chief cells of the parathyroid and parafollicular C cells of the 615 
thyroid, and control of ion transport in the kidney, is still being elucidated.  Although 616 
we have selected to investigate the modulatory effects of calcimimetics on three key 617 
signalling pathways that regulate some of the physiological actions of the CaSR, these 618 
pathways are not exhaustive.  For instance, G12/13-mediated cytoskeletal 619 
rearrangements are important for CaSR-mediated suppression of PTH release (Quinn 620 
et al., 2007) but experiments that measure G12/13-mediated membrane ruffling, for 621 
instance, are not amenable to high throughput screening techniques and have 622 
subsequently not been included in the present study.  Our ongoing work aims to 623 
extend these studies to examine activity across multiple pathways in primary cell 624 
lines, to establish the link between signalling bias and in vivo pharmacological and 625 
physiological calcimimetic effects.   626 
 627 
It must also be noted that allosterism may be influenced by the kinetics of ligand 628 
binding relative to the different time points underlying response generation in each 629 
experiment.  Thus, an alternative explanation for the observed bias is that each ligand 630 
stabilises the same state with different kinetics.  However, the same direction of bias 631 
towards Ca2+i mobilisation over pERK1/2 is also observed following preincubation of 632 
the CaSR with cinacalcet and NPS-R568 for 30 minutes prior to measurement of 633 
agonist-mediated receptor signalling (Davey et al., 2013).  Thus, differences in 634 A
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modulator bias in the different assays likely reflect true biased signalling and not an 635 
equilibrium artefact.  For the detection of agonism, the transient nature of agonist-636 
mediated Ca2+i mobilisation, pERK1/2 and indeed many other GPCR signalling 637 
responses means signalling will often subside before equilibrium binding can be 638 
reached.  Thus, the receptor may no longer elicit a response once true equilibrium is 639 
obtained.  Therefore, it is assumed that one of the most relevant responses for the 640 
purpose of detecting receptor signalling and indeed biased signalling is the response 641 
elicited upon first exposure of a cell to the activating agonist.   642 
 643 
In addition to differences in agonist effects and biased modulation of different 644 
signalling pathways, we found that AC-265347, unlike the other calcimimetics tested, 645 
was unable to restore expression of the G670E loss-of-expression mutant. Importantly, 646 
this and our previous study have identified unique ligand-biased profiles whereby a 647 
drug can positively modulate CaSR signalling and trafficking (cinacalcet, NPS-R568, 648 
calindol, R,R-calcimimetic B and nor-calcimimetic B),  negatively modulate CaSR 649 
signalling and positively modulate trafficking (NPS-2143) (Leach et al., 2013) or 650 
positively modulate signalling without affecting trafficking (AC-265347).  The 651 
inability of AC-265347 to rescue expression may be due to its lower lipophilicity, 652 
which makes it less likely to cross the cell membrane.  Thus, compartmentalisation of 653 
receptors away from the cell surface restricts its access to only a subset of the 654 
available receptor pool.  This represents an alternative means by which a drug can 655 
bias the activity of a receptor; one that is governed by its interaction with receptors 656 
that signal (cell surface receptors) versus those that can traffic to the cell surface 657 
(intracellular receptors). 658 
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The diverse pharmacological profile exhibited by each of the allosteric modulators 660 
offers exciting possibilities for their use beyond treatments for secondary 661 
K\SHUSDUDWK\URLGLVP  )RU LQVWDQFH IXWXUH LGHQWLILFDWLRQ RI SXUH ³WUDIILFNLQJ662 
PRGXODWRUV´PD\EHEHQHILFLDOLQGLVHDVHVWDWHVZKHUHUHGXFHG&D65H[SUHVVLRQKDV663 
been identified, such as colon cancer (Hizaki et al., 2011; Singh et al., 2012), and 664 
primary and secondary hyperparathyroidism (Cetani et al., 2000; Kifor et al., 1996; 665 
Yano et al., 2000).   Furthermore, drugs may be fine-tuned to the needs of distinct 666 
patients carrying naturally occurring CaSR mutations, depending on the impact of 667 
their mutation on receptor signalling and/or trafficking.   The ability to tailor drug 668 
therapies to patients harbouring naturally occurring mutations may become an 669 
important consideration not just for the CaSR, but also for other GPCRs.  Indeed, 670 
naturally occurring mutations in the glucagon-like peptide 1 receptor, for instance, 671 
engender signalling bias, with some mutations altering receptor coupling to only a 672 
subset of intracellular signalling pathways (Koole et al., 2011).  Thus, a 673 
pharmacogenomics approach may be essential for the future treatment of certain 674 
patient subtypes. 675 
 676 
In conclusion, the current study has characterised structurally diverse calcimimetics 677 
and identified distinct ligand-biased signalling engendered by different classes of 678 
compounds.  Although at present it is unclear which biased profile will be desirable in 679 
different disease states, the identification of biased ligands provides novel tools to 680 
probe the in vivo consequences of differentially promoting CaSR signalling and 681 
trafficking.  682 
 683 
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Figure 1  Structure of the CaSR allosteric modulators examined in this 925 
study. Calculated partition coefficient (CLog P) obtained from PerkinElmer 926 
ChemBioDraw software are shown. 927 
 928 
Figure 2 Structurally distinct calcimimetics potentiate Ca2+o-mediated 929 
receptor activation with different potencies. Ca2+o-mediated IP1 accumulation in 930 
the presence of 0 ( ȝ0 ȝ0 ȝ0 ȝ0 ), 931 
 ȝ0    ȝ0    ȝ0   DQG  ȝ0  ) cinacalcet (A), R,R-932 
calcimimetic B (B) and AC-265347 (C).  Data are mean + s.e.m from at least 4 933 
independent experiments performed in duplicate.  934 
 935 
Figure 3 Calcimimetics display distinct functional affinities and/or 936 
cooperativities for CaSR conformations that couple to different signalling 937 
pathways. Modulator functional affinities (functional pKB DQG FRRSHUDWLYLWLHV Įȕ938 
were determined as described in the Methods, by fitting the Ca2+o pEC50 in the 939 
absence and presence of modulator determined in Ca2+i mobilisation (white bars), 940 
pERK1/2 (grey bars) and IP1 accumulation (black bars) assays to an allosteric ternary 941 
complex model (equation 2).  The affinity of the modulator was unconstrained in each 942 
pathway. Statistical differences shown by asterisks are demonstrated where an F-test 943 
determined that the data were fitted best when the modulator affinities and 944 
cooperativies were different between the three pathways. Data are mean + s.e.m from 945 
at least 4 independent experiments performed in duplicate.    946 
 947 
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Figure 4 AC-265347 preferentially modulates pERK1/2 and IP1 948 
accumulation over Ca2+i mobilisation. Ca2+o-mediated Ca2+i-mobilisation (A), 949 
pERK1/2 (B) and IP1 accumulation (C) in the absence ( ) DQGSUHVHQFHRIȝ0 950 
( ) AC-$³ELDVSORW´'GHSLFWV$&-¶VSUHIHUHQWLDOPRGXODWLRQRI951 
pERK1/2 and IP1 accumulation versus Ca2+i-mobilisation. Ca2+o pEC50 in the absence 952 
and presence of modulator was determined in IP1 accumulation, Ca2+i mobilisation 953 
and pERK1/2 assays and fitted to an allosteric ternary complex model (equation 2) to 954 
determine 150 XY coordinates of points that defined the curve that best described the 955 
model.  The XY coordinates for the different pathways are plotted against one 956 
another, with IP1 accumulation or Ca2+i mobilisation data on the y-axis against 957 
pERK1/2 data on the x-axis.  Grey and black dashed lines join IP1 accumulation and 958 
Ca2+o mobilisation XY coordinates, respectively, corresponding to the effects of 0  959 
( ȝ0 ȝ0 ȝ0 ), 0.1 ȝ0 ȝ0 ), 1 960 
ȝ0 ȝ0 DQGȝ0 ) AC-265347.  The dotted line represents the line 961 
of identity, which is a theoretical representation of how the data would look if the 962 
pathways were modulated equally by AC-265347.   963 
 964 
Figure 5 Calcimimetics are agonists at the CaSR.  Activity of calcimimetics 965 
in the absence of ambient Ca2+o and Mg2+o measured in Ca2+i-mobilisation (closed 966 
circles) and IP1 accumulation assays (open circles).  Data are mean + s.e.m from 3 967 
independent experiments performed in triplicate. 968 
 969 
Figure 6 CaSR modulators differentially rescue the G670E loss-of-expression 970 
mutant.  Whereas overnight treatment with the calcimimetics has minimal effect on 971 
the expression of the WT CaSR in HEK cells, cinacalcet, NPS-R568, calindol, R,R-972 A
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calcimimetic B and nor-calcimimetic B rescue the expression of the G670E mutant.  973 
AC-265347 and S,R-calcimimetic B, however, do not rescue cell surface expression.  974 
Data are mean + s.e.m from at least 4 independent experiments. 975 
 976 
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Table 1. Pharmacological parameters that govern the allosteric activity of CaSR modulators in Ca
2+
i mobilisation, pERK1/2 and IP1 
accumulation assays.  The potency of Ca
2+
o in the presence of increasing concentrations of modulator was fitted to an allosteric ternary 
complex model (Equation 2) to quantify the equilibrium dissociation constant (pKB) and cooperativity (αβ) of the modulators at the human 
CaSR, using a model in which the binding affinity was not constrained across pathways. 
Grouped data analysis 
 Ca
2+
i mobilisation  pERK1/2 IP1 accumulation 
 pKB ±  s.e.m. (n) Logαβ ±  s.e.m. 
(αβ) 
pKB ±  s.e.m. (n) Logαβ ±  s.e.m. 
(αβ) 
pKB ±  s.e.m. (n) Logαβ ±  s.e.m. 
(αβ) 
Cinacalcet 5.98 ± 0.18 (18)
a
 0.66 ± 0.06 (4.6)
a
 5.93 ± 0.29 (13)
a
 0.46 ± 0.08 (2.9)
a
 6.14 ± 0.33 (4) 0.68 ± 0.13 (4.8) 
NPS-R568*  6.57 ± 0.19 (15) 0.59 ± 0.07 (3.9) 5.64 ± 0.18 (4) 0.71 ± 0.06 (5.1) 6.76 ± 0.24 (4) 0.64 ± 0.09 (4.3) 
Calindol* 6.33 ± 0.23 (4) 0.73 ± 0.10 (5.4) 5.16 ± 0.16 (4) 0.91 ± 0.08 (8.1) 6.35 ± 0.23 (4) 0.67 ± 0.09 (4.7) 
S,R-Calcimimetic B 5.53 ± 0.16 (4) 0.32 ± 0.03 (2.1) 5.31 ± 0.68 (3) 0.42 ± 0.20 (2.6) 5.18 ± 0.31 (3) 0.81 ± 0.14 (6.5) 
R,R-Calcimimetic B* 7.15 ± 0.17 (4) 0.27 ± 0.02 (1.9) 7.08 ± 0.18 (4) 0.47 ± 0.04 (3.0) 7.03 ± 0.54 (4) 0.50 ± 0.14 (3.2) 
nor-calcimimetic B 6.90 ± 0.25 (7) 0.30 ± 0.04 (2.0) 6.80 ± 0.42 (5) 0.32 ± 0.08 (2.1) 7.29 ± 0.58 (4) 0.45 ± 0.15 (3.0) 
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AC-265347* 6.42 ± 0.22 (5) 0.63 ± 0.08 (4.3) 6.26 ± 0.13 (4) 0.97 ± 0.07 (9.3) 7.99 ± 0.26 (4) 0.60 ± 0.09 (4.0) 
a
Data sets taken from those used in (Leach et al., 2013) 
* Significant difference in pKB and/or Logαβ between pathways (p<0.05, F test) 
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Table 2. Pharmacological parameters that govern calcimimetic agonism at the CaSR.  Agonist concentration-response curves were 
fitted to an operational model of agonism (Equation 3) (Black & Leff, 1983) to quantify the equilibrium dissociation constant (pKB) of the 
calcimimetics and their operational measure of agonism (τB).  
 Ca
2+
i mobilisation  IP1 accumulation  
 pKB ±  s.e.m. (n) LogτB ±  s.e.m. (τB) pKB ±  s.e.m. (n) LogτB ±  s.e.m. (τB) 
R,R-Calcimimetic B 6.77 ± 0.23 (3) -0.27 ± 0.04 (0.54) 6.48 ± 0.28 (3) -0.16 ± 0.06 (0.69) 
S,R-Calcimimetic B 5.44 ± 0.29 (3) -0.10 ± 0.10 (0.79) 5.89 ± 0.26 (3) -0.06 ± 0.07 (0.87) 
nor-calcimimetic B  6.44 ± 0.14 (3) -0.10 ± 0.03 (0.79) 5.61 ± 0.29 (3) -0.008 ± 0.09 (0.98) 
AC-265347 5.94 ± 0.14 (3) -0.02 ± 0.14 (0.95) 6.04 ± 0.18 (3) 0.08 ± 0.05 (1.1) 
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Table 3. Pharmacological properties of CaSR modulators at the naturally occurring G
670
E mutant.  Cell surface expression of the mutant 
following overnight treatment with modulator was determined by FACS analysis.  The potency of Ca
2+
o in Ca
2+
i mobilisation assays in the 
presence of increasing concentrations of modulator was fitted to an allosteric ternary complex model (Equation 2) to quantify the equilibrium 
dissociation constant (pKB) and cooperativity (αβ) of the modulators at the G
670
E mutant. 
 Cell surface expression (% WT) Ca
2+
i mobilisation 
 0 modulator 0.3 µM 3 µM pKB ±  s.e.m. (n) Logαβ ±  s.e.m. (αβ) 
Cinacalcet
 
 
 
 
12 ± 2 
74 ± 12 152 ± 39 6.00 ± 0.19 (7)
a 
0.59 ± 0.06 (3.9)
a 
NPS-R568 33 ± 9 126 ± 37 6.61 ± 0.14 (4) 0.74 ± 0.14 (5.5) 
Calindol 36 ± 7 112 ± 28 6.33 ± 0.31 (3) 0.53 ± 0.10 (3.4) 
R,R-calcimimetic B 62 ± 11 152 ± 40 5.27 ± 0.37 (4) 0.51 ± 0.12 (3.2) 
S,R-calcimimetic B 12 ± 3 14 ± 5 Not performed Not performed 
nor-calcimimetic B 28 ± 6 91 ± 27 6.21 ± 0.23 (3) 0.42 ± 0.06 (2.6) 
AC-265347 14 ± 3 18 ± 5 6.62 ± 0.23 (3) 0.72 ± 0.10 (5.2) 
a
Data sets taken from those used in (Leach et al., 2013)!
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